Skip Navigation

FDA approves Sarepta drug

In this video

SRPT

Squawk on the Street

FDA approves Sarepta drug

The FDA approves Sarepta muscular dystrophy drug. CNBC's Meg Tirrell reports the details.

00:32

Mon, Sep 19 201610:18 AM EDT

ServiceNow CEO on AI: Not a moment to think incrementally, this is a 'shift in the enterprise'

ServiceNow CEO on AI: Not a moment to think incrementally, this is a 'shift in the enterprise'

Nvidia CEO Jensen Huang: We're moving from world of software to producing digital intelligence

Nvidia CEO Jensen Huang: We're moving from world of software to producing digital intelligence

It's not a bull market outside of AI-related chips, says Ritholtz's Josh Brown

It's not a bull market outside of AI-related chips, says Ritholtz's Josh Brown

Here's why short-seller Spruce Point Capital is betting against Boot Barn

Here's why short-seller Spruce Point Capital is betting against Boot Barn

There's a 'strong case' for China entering a bull market, says KraneShares' Brendan Ahern

There's a 'strong case' for China entering a bull market, says KraneShares' Brendan Ahern

ServiceNow CEO on AI: Not a moment to think incrementally, this is a 'shift in the enterprise'

ServiceNow CEO on AI: Not a moment to think incrementally, this is a 'shift in the enterprise'

Nvidia CEO Jensen Huang: We're moving from world of software to producing digital intelligence

Nvidia CEO Jensen Huang: We're moving from world of software to producing digital intelligence

It's not a bull market outside of AI-related chips, says Ritholtz's Josh Brown

It's not a bull market outside of AI-related chips, says Ritholtz's Josh Brown

Here's why short-seller Spruce Point Capital is betting against Boot Barn

Here's why short-seller Spruce Point Capital is betting against Boot Barn

There's a 'strong case' for China entering a bull market, says KraneShares' Brendan Ahern

There's a 'strong case' for China entering a bull market, says KraneShares' Brendan Ahern